Trump’s FDA pick faces trouble from a key Republican over vaccines


Full story

President Donald Trump nominated Heidi Overton, a physician and top White House domestic policy aide, to lead the Food and Drug Administration on Wednesday. Less than a day later, her confirmation fight is already taking shape.

In announcing her nomination on Truth Social, Trump said Overton has “been a ROCKSTAR in my administration,” adding, “She is known to take on the HARDEST issues and bring me solutions that work best for the Country….We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES.”

Who is Heidi Overton?

As a White House aide, Overton regularly briefs the president on health issues.

She has become a familiar face alongside Trump as he’s made major changes to U.S. health policy, including last week when he signed an executive order aimed at reducing the number of routinely recommended childhood vaccinations.

At the time, Overton urged “blue states” to adopt what she called the Trump administration’s “gold standard” recommendations.

Now, Trump wants her to run the FDA — and her role in those vaccine changes is already drawing opposition.

A key Republican raises concerns

Overton will need Senate confirmation before taking over the FSDA, and one important Republican is already raising serious concerns.

Sen. Bill Cassidy, R-La., who chairs the committee that would consider her nomination, pointed directly to her role in the vaccine order, calling it “nonsensical” and saying her involvement is “almost disqualifying.”

“Her lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues,” Cassidy added.

Overton could also face questions about abortion.

Before joining the White House, she celebrated the Supreme Court decision overturning Roe v. Wade. Now, the FDA is reviewing the safety of mifepristone, the widely used abortion pill.

If confirmed, Overton would replace Marty Makary, who resigned in May after clashes with the White House over issues including vaping policy and access to abortion pills.

Round out your reading

Tags: , , ,

Straight Arrow
Fear No Fact.

Don't just take our word for it.


Center-rated reporting

According to media bias experts at AllSides

AllSides Center-rated reporting May 2026

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Why this story matters

The FDA, which regulates drugs, medical devices and food safety, is without confirmed leadership as a nominee faces early resistance from the Senate Republican who controls her confirmation hearing.

FDA leadership remains unsettled

Marty Makary resigned in May, and Overton's confirmation faces opposition from Sen. Bill Cassidy, who chairs the committee that would consider her nomination, leaving the agency without confirmed leadership.

Abortion pill review under scrutiny

The FDA is currently reviewing the safety of mifepristone, a widely used abortion pill, and Overton's past celebration of the Roe v. Wade reversal is expected to draw questions during confirmation.

Vaccine policy role flagged

Cassidy called Overton's involvement in Trump's executive order reducing routinely recommended childhood vaccinations "nonsensical" and described it as "almost disqualifying."

Straight Arrow
Fear No Fact.

Don't just take our word for it.


Center-rated reporting

According to media bias experts at AllSides

AllSides Center-rated reporting May 2026

Transparent and credible

Awarded a perfect reliability rating from NewsGuard

100/100

Welcome back to trustworthy journalism.

Find out more

Sources

  1. NBC News

Bias comparison

  • Not enough unique coverage from media outlets on the left to provide a bias comparison.
  • Media outlets in the center largely present a developing appointment and confirmation question.
  • Media outlets on the right emphasize more than 3,000 staff losses, “pro-MAHA” alignment, “pro-life” views, faster cures, and lower drug prices, echoing Trump’s “rockstar” praise and “America First” agenda.

Media landscape

Click on bars to see headlines

261 total sources

Key points from the Left

  • Dr. Heidi Overton, a medical doctor and deputy director of the White House Domestic Policy Council, was chosen by President Donald Trump to lead the Food and Drug Administration.
  • Overton is recognized as a trusted figure in the Trump administration and supports the president's health goals from his second term.
  • The new FDA commissioner will face challenges balancing Trump's priorities, Republican anti-regulatory views, and Health Secretary Robert F. Kennedy Jr.'s anti-corporate stance.
  • Trump praised Overton as a smart and respected 'rockstar' who will advance faster cures, innovation, lower drug prices, and support Kennedy's Make America Healthy Again movement.

Report an issue with this summary

Key points from the Center

  • On Wednesday, President Donald Trump announced his intent to nominate White House domestic policy aide Dr. Heidi Overton to lead the Food and Drug Administration. If confirmed, she would replace former commissioner Dr. Marty Makary, who resigned in May.
  • The FDA has operated without a permanent leader since Makary resigned in May 2026 following intense internal clashes. The agency has contended with the loss of more than 3,000 employees and division leaders over the past year.
  • A medical doctor and deputy director of the White House Domestic Policy Council, Overton is expected to advance the 'Make America Healthy Again' agenda. Trump wrote she will work to "RAPIDLY deliver on my priorities of FASTER Cures, INCREASED American Innovation, MAJOR Clinical Trial Reforms, LOWER Drug Prices."
  • Senate confirmation awaits Overton, where she will likely encounter scrutiny regarding her past comments on abortion pills and vaccine policies. Critics have questioned her lack of specific food or regulatory industry experience.
  • Navigating competing interests between Trump's priorities, anti-regulatory traditionalists, and Health Secretary Robert F. Kennedy Jr.'s anti-corporate posture remains a critical hurdle. Restoring institutional confidence after more than 3,000 staff departures will test the incoming commissioner.

Report an issue with this summary

Key points from the Right

  • President Donald Trump has selected Dr. Heidi Overton, a deputy director of the White House Domestic Policy Council, to lead the U.S. Food and Drug Administration following Marty Makary's resignation.
  • Dr. Overton holds a Ph.D. From Johns Hopkins University and has worked with Health and Human Services Secretary Robert F. Kennedy Jr. On health care policy initiatives.
  • Trump has praised Overton and indicated she will work to speed up cures, reform clinical trials, and lower drug prices.
  • Her nomination is expected to face Senate confirmation with scrutiny due to disputes over vaccine policies and staffing challenges at the FDA.

Report an issue with this summary

Other (sources without bias rating):

Powered by Ground News™

Sources

  1. NBC News